BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Das D, Hong J, Chen SH, Wang G, Beigelman L, Seiwert SD, Buckman BO. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorg Med Chem 2011;19:4690-703. [PMID: 21798747 DOI: 10.1016/j.bmc.2011.06.079] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
2 Shin MK, Kim TH, Ju K, Ha CY, Min HJ, Jung WT, Lee OJ. A case of sudden-onset hearing loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C. Korean J Hepatol 2009;15:370. [DOI: 10.3350/kjhep.2009.15.3.370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Sharifian MR, Kamandi S, Sima HR, Zaringhalam MA, Bakhshaee M. INF- α and ototoxicity. Biomed Res Int 2013;2013:295327. [PMID: 23984336 DOI: 10.1155/2013/295327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Gozdas HT, Karabay O. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. Indian J Pharmacol 2015;47:121-2. [PMID: 25821325 DOI: 10.4103/0253-7613.150377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Le V, Bader T, Fazili J. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nat Rev Gastroenterol Hepatol 2009;6:57-60. [DOI: 10.1038/ncpgasthep1317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Evans DeWald L, Starr C, Butters T, Treston A, Warfield KL. Iminosugars: A host-targeted approach to combat Flaviviridae infections. Antiviral Res 2020;184:104881. [PMID: 32768411 DOI: 10.1016/j.antiviral.2020.104881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tanaka M, Hasegawa S, Nakao S, Shimada K, Mukai R, Matsumoto K, Nakamura M. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLoS One 2019;14:e0217951. [PMID: 31593579 DOI: 10.1371/journal.pone.0217951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope 2021;131:1626-32. [PMID: 33491234 DOI: 10.1002/lary.29424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Eser Karlidag G, Karlidag T, Demirdag K, Keles E. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011;38:312-8. [PMID: 21216118 DOI: 10.1016/j.anl.2010.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]